News | News By Subject | News by Disease News By Date | Search News

Cystic fibrosis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study     8/17/2016
Vertex (VRTX) and Moderna Hammer Out $315 Million+ Deal to Treat Cystic Fibrosis Using mRNA Technology     7/6/2016
FDA Spurns Vertex (VRTX) Application for Expanded Use of Kalydeco     2/5/2016
How Vertex (VRTX)'s Long-Term $500K Gamble Paid Off with a $30 Billion Return     11/18/2015
Vertex (VRTX)'s Success Spurs Startups Corbus and Pulmatrix to Enter Cystic Fibrosis Market     8/18/2015
Watch Out Gilead (GILD), Investors Feel Vertex (VRTX) May Be Biogen (BIIB)'s Good Fit     8/4/2015
Vertex (VRTX) Gets FDA Approval for $259K Per Year CF Drug     7/7/2015
Vertex (VRTX) Poised to Become Profitable Following Expected FDA Approval of Orkambi     7/1/2015
Tiny Parion Sciences Wrangles Lung Pact Worth $1.2 Billion From Vertex (VRTX)     6/8/2015
Corbus Will Interview Twice as Many Candidates in 2015 as Its Ranks Grow     5/29/2015
Your Analyst-Vetted Guide to the Five Blockbuster Drugs the FDA May Approve This Summer     5/28/2015
Vertex (VRTX) Soars After Hours as FDA Panel Backs Cystic Fibrosis Drug Orkambi     5/15/2015
Investors Hold Their Breath as Vertex (VRTX) Defends Newly Branded Cystic Fibrosis Treatment to the FDA     5/12/2015
Heart-Stopping Morning Leads to Vertex (VRTX) Rise As FDA News Sees Positives     5/11/2015
Tiny Corbus Looks to Give Vertex (VRTX) Some Competition With Experimental Cystic Fibrosis Drug     5/6/2015

News from Around the Web
New Life Form Discovered In Saliva Is Linked To Human Disease, University of Washington Study     6/27/2016
VisiVest, A New Connected High-Frequency Chest-Wall Oscillation System, Hill-Rom Reveals     6/22/2016
The Importance Of Implementing CF Newborn Screening Reinforced, McGill University Study     5/5/2016
Researchers Build Promising CF Diagnostic System Using Microsoft's Xbox Kinect Sensors     3/30/2016
Fast, Accurate Cystic Fibrosis Test Developed At Stanford University     2/2/2016
Why Investors Shouldn't Freak Out Over Vertex (VRTX)'s Latest Trial Results     3/24/2015
Garlic Could Help Cure Lung Infection, University of Edinburgh Study     2/25/2015
University of Pittsburgh-Led Study Suggests Cystic Fibrosis Is Two Diseases, One Doesn’t Affect Lungs     7/23/2014
Cystic Fibrosis And Diabetes Link Explained, Lund University Study     6/3/2014
New Drug Target Found for Cystic Fibrosis Lung Disease, BC Children's Hospital Study     11/8/2012
Sea Sponge Chemical Fixes Cystic Fibrosis Defect, McGill University Study     10/29/2012
Differences Seen in Lung Microbes of Cystic Fibrosis Patients, Stanford University Study     10/1/2012
Big Advance Against Cystic Fibrosis: Stem Cell Researchers Create Lung Surface Tissue in a Dish, Massachusetts General Hospital Study     4/6/2012
Student, 16, Invents New Drug Cocktail to Fight Cystic Fibrosis, Wins Canadian Biotech Challenge, National Research Council of Canada laboratories Reveals     5/12/2011
Cystic Fibrosis Patients May Benefit From Combination Therapy Which Provides Hope For Cure Of Dangerous Infections, McMaster University Study     4/25/2011

Press Releases
Pulmatrix Receives Orphan Drug Designation From The FDA For Inhaled Drug To Treat Pulmonary Fungal Infections In Cystic Fibrosis Patients     8/18/2016
Children's Hospital Los Angeles Release: DNA Sequencing Uncovers Latent Risk For Developing Cystic Fibrosis     7/26/2016
PTC Therapeutics (PTCT) Provides Regulatory Update On Translarna (Ataluren)     7/25/2016
ProQR Therapeutics B.V. (PRQR) Receives Fast Track Designation From FDA For QR-010 For Cystic Fibrosis     7/19/2016
ProQR Therapeutics B.V. (PRQR) To Release Topline Data From Proof Of Concept Study Of QR-010 In Cystic Fibrosis Patients At NACFC     6/21/2016
Concert Pharmaceuticals, Inc. (CNCE) Presents CTP-656 Phase I Results At European Cystic Fibrosis Conference     6/13/2016
PTC Therapeutics (PTCT) Release: New Analyses From Phase 3 Study 009 Of Translarna (Ataluren) In Patients With Cystic Fibrosis Presented At 39th European Cystic Fibrosis Conference     6/10/2016
Vertex (VRTX) Announces Presentations Of Data For KALYDECO (Ivacaftor) And ORKAMBI® (Lumacaftor/Ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference     6/10/2016
Concert Pharmaceuticals, Inc. (CNCE) Presents CTP-656 Phase I Results At European Cystic Fibrosis Conference     6/10/2016
Vertex (VRTX) Release: FDA Accepts For Priority Review Supplemental New Drug Application For The Use Of ORKAMBI (Lumacaftor/Ivacaftor) In Children With Cystic Fibrosis Ages 6 To 11 Who Have Two Copies Of The F508del Mutation     5/31/2016
Health Canada Authorizes ProMetic Life Sci (PFSCF.PK) To Proceed With Its PBI-4050 Clinical Trial In Patients With Cystic Fibrosis     5/18/2016
Nivalis Therapeutics Announces First Patient Dosed In Second Phase II Study Of N91115 For Treatment Of Cystic Fibrosis     5/17/2016
Galapagos (GLPG.BR) Starts Phase 1 Study With Potentiator GLPG2451 For CF     5/10/2016
Acetylon Pharmaceuticals Publishes New Mechanism For The Treatment Of Sickle Cell Disease/Beta-Thalassemia With Selective HDAC1/2 Inhibition In Plos One     5/4/2016
Concert Pharmaceuticals, Inc. (CNCE) Announces Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-656, Lead Candidate For The Treatment Of Cystic Fibrosis     4/29/2016

//-->